226 related articles for article (PubMed ID: 17535916)
1. Small-molecule activators of RNase L with broad-spectrum antiviral activity.
Thakur CS; Jha BK; Dong B; Das Gupta J; Silverman KM; Mao H; Sawai H; Nakamura AO; Banerjee AK; Gudkov A; Silverman RH
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9585-90. PubMed ID: 17535916
[TBL] [Abstract][Full Text] [Related]
2. Specificity and Mechanism of Coronavirus, Rotavirus, and Mammalian Two-Histidine Phosphoesterases That Antagonize Antiviral Innate Immunity.
Asthana A; Gaughan C; Dong B; Weiss SR; Silverman RH
mBio; 2021 Aug; 12(4):e0178121. PubMed ID: 34372695
[TBL] [Abstract][Full Text] [Related]
3. The 2-5A system in viral infection and apoptosis.
Castelli J; Wood KA; Youle RJ
Biomed Pharmacother; 1998; 52(9):386-90. PubMed ID: 9856285
[TBL] [Abstract][Full Text] [Related]
4. High yield synthesis, purification and characterisation of the RNase L activators 5'-triphosphate 2'-5'-oligoadenylates.
Morin B; Rabah N; Boretto-Soler J; Tolou H; Alvarez K; Canard B
Antiviral Res; 2010 Sep; 87(3):345-52. PubMed ID: 20547186
[TBL] [Abstract][Full Text] [Related]
5. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L.
Malathi K; Paranjape JM; Bulanova E; Shim M; Guenther-Johnson JM; Faber PW; Eling TE; Williams BR; Silverman RH
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14533-8. PubMed ID: 16203993
[TBL] [Abstract][Full Text] [Related]
6. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.
Player MR; Torrence PF
Pharmacol Ther; 1998 May; 78(2):55-113. PubMed ID: 9623881
[TBL] [Abstract][Full Text] [Related]
7. A convenient and sensitive fluorescence resonance energy transfer assay for RNase L and 2',5' oligoadenylates.
Thakur CS; Xu Z; Wang Z; Novince Z; Silverman RH
Methods Mol Med; 2005; 116():103-13. PubMed ID: 16000857
[TBL] [Abstract][Full Text] [Related]
8. The Role of Phosphodiesterase 12 (PDE12) as a Negative Regulator of the Innate Immune Response and the Discovery of Antiviral Inhibitors.
Wood ER; Bledsoe R; Chai J; Daka P; Deng H; Ding Y; Harris-Gurley S; Kryn LH; Nartey E; Nichols J; Nolte RT; Prabhu N; Rise C; Sheahan T; Shotwell JB; Smith D; Tai V; Taylor JD; Tomberlin G; Wang L; Wisely B; You S; Xia B; Dickson H
J Biol Chem; 2015 Aug; 290(32):19681-96. PubMed ID: 26055709
[TBL] [Abstract][Full Text] [Related]
9. RNase L dimerization in a mammalian two-hybrid system in response to 2',5'-oligoadenylates.
Naik S; Paranjape JM; Silverman RH
Nucleic Acids Res; 1998 Mar; 26(6):1522-7. PubMed ID: 9490801
[TBL] [Abstract][Full Text] [Related]
10. RNase L plays a role in the antiviral response to West Nile virus.
Scherbik SV; Paranjape JM; Stockman BM; Silverman RH; Brinton MA
J Virol; 2006 Mar; 80(6):2987-99. PubMed ID: 16501108
[TBL] [Abstract][Full Text] [Related]
11. 2-5A induces a conformational change in the ankyrin-repeat domain of RNase L.
Nakanishi M; Goto Y; Kitade Y
Proteins; 2005 Jul; 60(1):131-8. PubMed ID: 15849753
[TBL] [Abstract][Full Text] [Related]
12. A novel mechanism of RNase L inhibition: Theiler's virus L* protein prevents 2-5A from binding to RNase L.
Drappier M; Jha BK; Stone S; Elliott R; Zhang R; Vertommen D; Weiss SR; Silverman RH; Michiels T
PLoS Pathog; 2018 Apr; 14(4):e1006989. PubMed ID: 29652922
[TBL] [Abstract][Full Text] [Related]
13. RNase L Antiviral Activity Is Not a Critical Component of the Oas1b-Mediated Flavivirus Resistance Phenotype.
Madden JC; Cui D; Brinton MA
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462564
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L.
Park IH; Kwon YC; Ryu WS; Ahn BY
Antiviral Res; 2014 Apr; 104():118-27. PubMed ID: 24509240
[TBL] [Abstract][Full Text] [Related]
15. Small self-RNA generated by RNase L amplifies antiviral innate immunity.
Malathi K; Dong B; Gale M; Silverman RH
Nature; 2007 Aug; 448(7155):816-9. PubMed ID: 17653195
[TBL] [Abstract][Full Text] [Related]
16. The 2'-5'-oligoadenylate synthetase 3 enzyme potently synthesizes the 2'-5'-oligoadenylates required for RNase L activation.
Ibsen MS; Gad HH; Thavachelvam K; Boesen T; Desprès P; Hartmann R
J Virol; 2014 Dec; 88(24):14222-31. PubMed ID: 25275129
[TBL] [Abstract][Full Text] [Related]
17. Homologous 2',5'-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity.
Zhang R; Jha BK; Ogden KM; Dong B; Zhao L; Elliott R; Patton JT; Silverman RH; Weiss SR
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):13114-9. PubMed ID: 23878220
[TBL] [Abstract][Full Text] [Related]
18. Solid-phase synthesis of 5'-triphosphate 2'-5'-oligoadenylates analogs with 3'-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.
Thillier Y; Stevens SK; Moy C; Taylor J; Vasseur JJ; Beigelman L; Debart F
Bioorg Med Chem; 2013 Sep; 21(17):5461-9. PubMed ID: 23810677
[TBL] [Abstract][Full Text] [Related]
19. Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation.
Thornbrough JM; Jha BK; Yount B; Goldstein SA; Li Y; Elliott R; Sims AC; Baric RS; Silverman RH; Weiss SR
mBio; 2016 Mar; 7(2):e00258. PubMed ID: 27025250
[TBL] [Abstract][Full Text] [Related]
20. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system.
Castelli JC; Hassel BA; Wood KA; Li XL; Amemiya K; Dalakas MC; Torrence PF; Youle RJ
J Exp Med; 1997 Sep; 186(6):967-72. PubMed ID: 9294150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
